SC-0191

Phase Ib: Primary objective: To evaluate the safety and tolerability of SC0191 combined with gemcitabine or paclitaxel in patients with advanced ovarian cancer, to determine the Phase II clinical recommended dose (RP2D) of SC0191 in the treatment of SC0191 combined with gemcitabine or paclitaxel. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of SC0191 combined with gemcitabine or paclitaxel in patients with advanced ovarian cancer; 2. To evaluate the preliminary anti-tumor activity of SC0191 combined with gemcitabine or paclitaxel in patients with advanced ovarian cancer. Exploratory objectives: 1. To explore the correlation between predictive biomarkers and the anti-tumor activity of combined treatment; 2. To explore the correlation between changes in pharmacodynamic biomarkers and SC0191 exposure. Phase II: Primary objective: To evaluate the safety and tolerability of SC0191 combined with gemcitabine or paclitaxel in patients with advanced platinum-resistant or platinum-refractory recurrent high-grade serous ovarian cancer. Secondary objectives: 1. To evaluate the anti-tumor activity of SC0191 combined with gemcitabine or paclitaxel in patients with advanced platinum-resistant or platinum-refractory recurrent high-grade serous ovarian cancer; 2. To evaluate the pharmacokinetic (PK) characteristics of SC0191 combined with gemcitabine or paclitaxel in patients with advanced ovarian cancer. Exploratory objectives: 1. To explore the correlation between predictive biomarkers and the anti-tumor activity of combination therapy; 2. To explore the correlation between changes in pharmacodynamic biomarkers and SC0191 exposure.